A New Standard for Copay Excellence: Q&A with Brian Laird
Pharmaceutical manufacturers are confronting escalating out‑of‑pocket costs, high‑deductible plans and fragmented payer rules, prompting a shift from static copay reimbursements to strategic, data‑driven solutions. EVERSANA, which already processes over 12 million claims for 1.5 million patients, launched its Intelligent Copay Solution to give manufacturers real‑time spend visibility, AI‑powered fraud detection and multi‑pathway claim routing. The platform moves copay programs from transactional services to integrated financial tools that protect access while controlling risk. Laird predicts the next five years will see copay models become increasingly adaptive, patient‑centric and analytics‑focused.
How Are Regulatory Factors Impacting Biosimilars
The FDA issued draft guidance in March that would drop certain pharmacokinetic (PK) studies for biosimilars, aiming to lower development costs. At the same time, the Inflation Reduction Act (IRA) and most‑favored‑nation (MFN) pricing provisions are reshaping how manufacturers price...
Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell — Episode 251
In episode 251 of the Xtalks Life Science Podcast, Kevin Caldwell, CEO and co‑founder of Ossium Health, discusses the company’s pioneering off‑the‑shelf bone‑marrow therapy derived from deceased organ donors. The treatment aims to solve long‑standing clinical and logistical hurdles in...
Viewpoint: CRISPR and mRNA — Under Attack by Technology Skeptics — Poised to Save Millions of Children with Rare Diseases
Rare genetic diseases affect roughly 25 million Americans and generate about $400 billion in annual medical costs, yet fewer than five percent have FDA‑approved therapies. The scarcity of treatments stems from the economics of drug development for tiny patient pools. Recent breakthroughs...
Major Organoids Companies Plus Latest TechBio News
The latest TechBio briefing spotlights the fastest‑growing private organoid firms, highlighting recent Series A‑C rounds that collectively raised over $500 million. Leaders such as OrganoTech, CellSphere, and BioMimic are scaling production pipelines to meet demand from pharma, diagnostics, and personalized‑medicine partners. The...
Sonodynamic Therapy with Ferrocene-Modified Frameworks Targets Breast Cancer Metastasis
Researchers at Beijing Institute of Technology have engineered ferrocene‑modified covalent organic frameworks (mCOFs) that act as ultrasound‑activated sonosensitizers. When combined with sonodynamic therapy, the nanoplatform reduces breast cancer cell viability to 24.3% and drives apoptosis above 84%, while simultaneously generating...
Top 20 Most Innovative Healthcare Companies in 2026, Per Fast Company
Fast Company’s 2026 list spotlights the 20 most innovative healthcare firms, ranging from biotech pioneers like Children’s Hospital of Philadelphia’s CRISPR therapy to digital‑health platforms such as Lantern and Maven Clinic. The rankings arrive amid a surge in drug approvals—46...
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
AbbVie signed an exclusive licensing deal with China’s Haisco Pharmaceutical to develop, manufacture and sell a suite of novel pain compounds outside mainland China, Hong Kong and Macau. The agreement provides Haisco $30 million upfront and up to $715 million in milestone payments,...
Fordham 33 (Report 4): Life Sciences and Healthcare Innovation
A multinational panel at Fordham’s IPKat event dissected life‑science patent strategies across the U.S., Europe, Japan and the upcoming Unified Patent Court. Speakers highlighted how European protocol disclosures reveal methods but not results, making anticipatory rejections rare, while U.S. product‑for‑use...
NEW STUDY: Frog-Derived Gut Bacterium Completely Eradicates 100% of Tumors After a Single Dose in Mice
A peer‑reviewed study in *Gut Microbes* reports that a single intravenous dose of the frog‑derived gut bacterium Ewingella americana eradicated colorectal tumors in 100% of immunocompetent mice. The live microbe outperformed both doxorubicin chemotherapy and anti‑PD‑L1 checkpoint blockade, achieving complete...
New CellCelector CLD Takes You From Thousands of Candidates to the Top Clone, Faster
German biotech equipment maker Sartorius has launched the CellCelector CLD, an automated imaging and cell isolation platform that accelerates monoclonal cell line development. The system combines high‑speed scanning, advanced imaging and gentle clone retrieval to screen up to 885 nanowell...
BHV-2100
Researchers from KU Leuven, CISTIM Leuven and Biohaven Therapeutics have announced that an oral TRPM3 antagonist has entered Phase 2 clinical testing for the acute treatment of migraine. The program leveraged a cell‑based high‑throughput screen of more than 200,000 compounds to...
How GLP-1s Are Shifting Pharma Commercialization Trends
The GLP‑1 class has evolved from a niche injectable therapy to a high‑volume market that now includes oral formulations, prompting pharma to pivot toward larger total addressable markets. Over the past decade the industry focused on ultra‑rare, high‑price drugs, but...
A Modular, Synthetic Origin of Replication
Researchers at Rice University have engineered a synthetic origin of replication, SynORI, that replaces the native ColE1 feedback loop with programmable RNA regulators. The modular design yields six orthogonal plasmid compatibility groups that can coexist in E. coli for at least...
The Next Frontier in Precision Oncology
Precision oncology is shifting from static, single‑biopsy analyses toward dynamic, multi‑omics platforms that integrate genomics, proteomics, spatial biology and longitudinal clinical data. Over the next decade, AI will move from pattern‑recognition to causal reasoning, offering clinicians interpretable predictions that anticipate...
The FDA Said NO to a New Vaccine; Then Suddenly Said YES; and the Guy Who Said NO Was Gone.
The FDA initially refused to review an experimental RNA flu vaccine, then abruptly reversed its stance after apparent pressure from the White House. The agency’s vaccine chief left the organization shortly after the policy shift, fueling speculation about internal conflict....
The Biotech Bi-Weekly: Expanding the Reach of T-Cell Engagers in Solid Tumors, a Next-Generation Chemiluminescent Immunoassay Platform and AACR Exhibitor...
The biotech bi‑weekly highlights several product launches and site expansions unveiled at the AACR Annual Meeting. Deck Bio introduced a multi‑target T‑cell engager platform aimed at overcoming heterogeneity in solid‑tumor immunotherapy. Abcam released SimpleStep Ignite™, a chemiluminescent ELISA that delivers...
Does the History of Insulin Rhyme with GLP-1s?
Liam Shaw’s essay draws a parallel between the debut of insulin and today’s GLP‑1 receptor agonists, arguing that both transformed their respective diseases while spawning new complexities. Insulin’s miracle cure introduced issues of affordability, access, and treatment intensification, a pattern...
How Serious Is the Biosimilar Void?
The FDA released a draft guidance in March 2026 that would drop certain pharmacokinetic (PK) studies, easing biosimilar development and cutting costs. Samsung Bioepis SVP Thomas Newcomer says a biosimilar void still exists in the U.S., especially for mid‑volume and...
Building Operational Visibility in Clinical Trials: Q&A with Deepak Prakash
Identiv VP Deepak Prakash explains how RFID and Bluetooth‑enabled tracking is reshaping clinical trial operations by delivering continuous, real‑time visibility of assets, samples, and shipments. The technology replaces fragmented, manual data entry with automated condition monitoring, cutting reconciliation costs and...
Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.
Johnson & Johnson’s Tecvayli (teclistamab) combined with Darzalex Faspro (daratumumab) achieved an 83% reduction in disease progression or death in a Phase III trial for relapsed/refractory multiple myeloma. The study, presented at ASH, reported a hazard ratio of 0.17, higher response rates,...
The Secret History of the FDA
The Brownstone Institute’s latest post argues that the FDA was created as an industry‑controlled agency to rescue failing meat‑packing and biologics sectors, embedding regulatory capture from its inception. It claims this origin explains why reforms face entrenched resistance and why...
Boehringer Ingelheim Launches LENZELTA Mastitis Vaccine for Dairy Cattle in European Union
Boehringer Ingelheim has secured an FDA Emergency Use Authorization for its IVOMEC® 1% ivermectin injection, allowing it to prevent New World screwworm infestations in cattle at key intervention points. The EUA permits treatment within 24 hours of birth, at castration,...
Sequence Identities and Functional Definitions - Where Is the Limit? (T 0137/24)
The EPO Board of Appeal in T 0137/24 upheld a cannabis‑producing yeast patent by ruling that selecting a higher amino‑acid sequence identity from a convergent list does not add matter. The board found the claim’s functional definition of enzyme activity sufficient,...
Biden FDA Knew About COVID Vaccine Stroke Risk and Kept Americans in the Dark
Senate investigators reviewing roughly 2,000 pages of federal records say the FDA and CDC identified a potential ischemic‑stroke risk linked to Pfizer’s bivalent COVID‑19 booster for adults over 65 as early as October 2022. The agencies documented 226 stroke cases...
![Oral Wegovy Sounds Easy, but the Reality Is More Complicated [PODCAST]](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/016265f036964b075db4a0e7e7a191dc.webp)
Oral Wegovy Sounds Easy, but the Reality Is More Complicated [PODCAST]
Oral Wegovy, the first FDA‑approved semaglutide pill, delivers rapid weight loss and metabolic improvements, but patients often experience nausea, constipation, reflux, and variable results after discontinuation. Recent pharmacovigilance data reveal a heightened signal for non‑arteritic anterior ischemic optic neuropathy, especially...
IMPORTANT REMINDER: Pfizer Whistleblower Fired Hours After Reporting “Nightmare” COVID Vaccine Trial
Brook Jackson, a senior associate at Ventavia Research Group, disclosed serious protocol breaches in Pfizer’s COVID‑19 vaccine trial, including mislabeled specimens and deliberate unblinding of participants. She reported these violations to the FDA on September 25 and was terminated by Ventavia...
Loyal Raises $100 Million: Dog Longevity Drugs Targeting IGF-1 and PPAR Pathways
Loyal, a veterinary biotech firm, announced a $100 million financing round to advance its canine longevity platform. The company targets the IGF‑1 and PPAR pathways to develop drugs that extend the lifespan of senior and large‑breed dogs. It has secured conditional...
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
The FDA issued a second complete response letter rejecting Replimune’s biologics license application for RP1 combined with nivolumab in advanced melanoma, citing insufficient data to isolate RP1’s contribution. Replimune’s CEO warned of job cuts and a scale‑back of U.S. manufacturing....
Kailera Therapeutics (KLRA) IPO Deck
Kailera Therapeutics (KLRA) is preparing an initial public offering to fund its GLP‑1‑based obesity drug platform, which includes both injectable and oral candidates. The company’s pipeline spans multiple clinical stages, from early‑phase studies to late‑stage trials, positioning it to capture...
Sarcopenia -- New Clues
Recent preclinical and clinical work links low‑grade inflammation to age‑related muscle loss, or sarcopenia, and shows that ibuprofen can blunt this process. In 20‑month‑old rats, a five‑month ibuprofen regimen cut inflammatory markers by up to 60% and boosted post‑prandial muscle...
Fragments vs the E3 Ligase KLHL12
Researchers at Vanderbilt screened 13,824 fragments against the E3 ligase KLHL12, a protein overexpressed in many cancers but absent from heart tissue. The campaign yielded 35 initial hits, with compound 7k emerging as the most potent, displaying sub‑micromolar affinity in...
Orforglipron
Orforglitron, an oral non‑peptide GLP‑1 receptor partial agonist developed by Eli Lilly and Chugai, received FDA approval for chronic weight management. The drug distinguishes itself from oral semaglutide by requiring no fasting or special dosing constraints, enabling once‑daily administration. Clinical trials...
Researchers Use Nanomaterials and Ultrasound to Create Light Inside the Body
Stanford researchers have created a noninvasive method that uses focused ultrasound to activate biocompatible ceramic nanoparticles, generating light at any point inside the body. The proof‑of‑concept, demonstrated in mice, produced blue 490 nm light that could stimulate neurons and mimic photodynamic...
Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies
Leukogene Therapeutics announced two poster presentations at the 2026 AACR Annual Meeting in San Diego, showcasing its MHC class II‑engager immunotherapy candidates for acute myeloid leukemia and pancreatic cancer. The posters will be displayed during the Immunology session on bi- and...
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who...
Daiichi Sankyo and Merck have received FDA acceptance and Priority Review for the Biologics License Application of ifinatamab deruxtecan, a first‑in‑class B7‑H3‑directed antibody‑drug conjugate, targeting adult patients with extensive‑stage small cell lung cancer (ES‑SCLC) who progressed after platinum chemotherapy. The...
Module 3 Quiz
Drug Hunter’s online learning platform has released a Module 3 quiz covering the Hit Discovery section of its pharmaceutical curriculum. The quiz is part of a broader, subscription‑based course that guides users through early‑stage drug‑target identification. Learners must sign in or...
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis will showcase its ultrasensitive NeXT Personal ctDNA assay at the AAC 2026 meeting, including an oral presentation on neoadjuvant pembrolizumab in high‑risk colorectal cancer. The company will also debut Real‑Time Variant Tracker, a new MRD test option that longitudinally monitors therapy‑resistance...
Living, 3D-Printed Biological Knee Replacement Advances to Preclinical Testing
Columbia University researchers have received ARPA‑H’s green light to move their living, 3‑D‑printed knee implant, NOVAKnee, into preclinical testing. The device combines a biodegradable scaffold with patient‑derived stem cells that regenerate cartilage and bone after implantation. Designed to address the...
Cartherics and Catalent Expand Commercial License Agreement
Cartherics and Catalent have signed an amended commercial license agreement granting Cartherics access to Catalent's cGMP‑compliant iPSC line for manufacturing its CAR‑NK cell therapies, including lead candidate CTH‑401. The partnership enables Cartherics to use the line for development, clinical trials,...
GLP-1 Tablets and the Shift in Discourse About Obesity
Foundayo, the first oral non‑peptide GLP‑1 tablet, received FDA approval last week, marking a new chapter in obesity treatment and intensifying competition with Novo Nordisk’s Wegovy pill. The launch coincides with a measurable shift in media coverage: mentions of obesity...
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
Almirall, a global medical dermatology company, has expanded its partnership with the Barcelona Supercomputing Center (BSC) under the BSC Connects program. The new framework, running through 2026, gives Almirall access to BSC’s AI and high‑performance computing resources, including the MareNostrum 5...
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
Recent enrollment shortfalls in Pfizer/BioNTech COVID‑19 and Lyme vaccine studies underscore how operational flaws can derail promising drugs. Matt Holms, VP of commercial, patient engagement and recruitment at Citeline, explains that modern trial design must integrate real‑world data, AI‑driven patient...
#387 – AMA #83: Peptides—Evaluating the Science, Safety, and Hype in a Rapidly Growing Field
Peter’s AMA on gray‑market peptides demystifies a fast‑growing, often misunderstood segment of the wellness industry. He introduces a four‑point framework—mechanism, evidence, safety, and regulatory status—to assess any peptide claim. The episode walks through real‑world case studies such as SS‑31, melanotan‑II,...
Aspirin May Fight Cancer — But Not for the Reason You Think
Researchers at Tahoe Therapeutics assembled a 100‑million‑cell dataset to ask whether drugs can push cancer cells back toward a normal gene program. Using this approach, they confirmed known colon‑cancer therapies and discovered that sodium salicylate—aspirin without its acetyl group—reverses cancer‑state...
FDA’s Fiscal Year 2027 Budget Is Chock-Full of Legislative Proposals – Especially on Hatch-Waxman and the BPCIA
The FDA’s FY2027 budget request bundles 27 legislative proposals into its Justification of Estimates for Appropriations Committees, a sharp increase from prior years. Highlights include allowing U.S. generic manufacturers to file Paragraph IV certifications a month earlier, deeming all approved...
Weekly Reads: Federal Stem Cell Charges Disappear, SCBEM Ethics, Diet & MYCN Cancer, How to Make a Nose
The article examines the abrupt dismissal of former South Carolina lawmaker Stephen Goldfinch’s federal stem‑cell charge, underscoring the uneven enforcement of unapproved cellular therapies. It contrasts this with a pending federal indictment targeting peptide manufacturers, especially BPC‑157, highlighting regulatory blind...
How Pfizer Created More Depressed People
In the early 1990s Pfizer launched Zoloft and deliberately reshaped public and medical perceptions of depression to expand its market. The company promoted a view that ordinary sadness was a chemical imbalance requiring medication, targeting primary‑care physicians as prescribers. This...
Progesterone in MHT for Protection Against Endometrial Cancer
Recent analysis of menopausal hormone therapy (MHT) highlights a tension between breast‑cancer safety and endometrial risk. Observational data from France’s E3N cohort found that women using oral micronized progesterone for five or more years faced a 2.7‑fold increase in endometrial...
Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus...
Corcept Therapeutics presented final overall survival results from the phase 3 ROSELLA trial, showing that Lifyorli™ (relacorilant) combined with nab‑paclitaxel cuts the risk of death by 35 percent and adds 4.1 months to median survival versus chemotherapy alone. The regimen met both overall...